US equities |
NVDA $170.76 ▼-4.43% AMD $521.91 ▲+2.62% MU $723.78 ▼-1.28% SPCX $142.19 ▲+0.08% SNDK $874.13 ▼-1.40% TSLA $375.68 ▼-0.63% AMZN $270.00 ▲+1.15% AAPL $349.20 ▼-0.42%
FinancialContent

Scribe Therapeutics Inc. - Common Stock (NQ:SCTX)

16.86 +0.18 (+1.08%)
Delayed Quote Updated: 9:53 AM EST, Nov 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Scribe Therapeutics Inc. - Common Stock

News headline image
Cathie Wood Bought Just 3 Stocks On Monday; Here They Are ↗
The aggressive growth instructor was picky with her purchases to kick off the new trading week. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
From Scribe Therapeutics Inc.
Via GlobeNewswire
News headline image
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026
From Scribe Therapeutics Inc.
Via GlobeNewswire
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Ark Invest added to three existing positions on Monday, all of them down sharply from recent highs. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
From Scribe Therapeutics Inc.
Via GlobeNewswire
News headline image
Scribe Therapeutics to Participate in Upcoming Investor Conferences
From Scribe Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure... 
Via Benzinga
News headline image
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
From Scribe Therapeutics Inc.
Via GlobeNewswire